Sangui Biotech International, Inc. (SGBI) is a publicly traded company in the Healthcare sector, operating within the Drug Manufacturers - Specialty & Generic industry. The company is headquartered in Hamburg, Germany. The current CEO is Thomas Striepe.
SGBI has IPO date of 1997-03-27, listed on the Other OTC, a market capitalization of $41.98K.
Sangui Biotech International, Inc., through its subsidiary, Sangui BioTech GmbH, develops hemoglobin-based artificial oxygen carriers for use as blood additives, blood volume substitutes, and variant products. The company's artificial oxygen carriers provide oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia, or blood loss, as well as chronic wounds. It also offers nano formulations for the regeneration of skin, including skin moisturization and enhanced skin elasticity; Chitoskin wound pads for supporting wound healing; and Hemospray wound spray, a medical product that is used for the healing of chronic wounds. The company sells its wound spray products under the Granulox brand name primarily in Europe and Mexico; and cosmetics products through internet shop. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
